Warning: preg_replace_callback(): Compilation failed: invalid range in character class at offset 22 in /customers/4/5/8/leaddiscoverysiena.it/httpd.www/wp-content/plugins/so-widgets-bundle/base/siteorigin-widget.class.php on line 841Warning: preg_replace_callback(): Compilation failed: invalid range in character class at offset 22 in /customers/4/5/8/leaddiscoverysiena.it/httpd.www/wp-content/plugins/so-widgets-bundle/base/siteorigin-widget.class.php on line 841

A great week for LDS at Bio 2019 in Philadelphia

LDS was present at the Bio 2019 in Philadelphia, June 3-6

The 2019 took place in Philadelphia, Pennsylvania this year. BIO2019 welcomed over 17,000 attendees in biotech and pharma from more than 65 countries and was a great opportunity for LDS to for unparalleled partnering and networking. LDS attended Bio 2019 together with Invest in Tuscany, a network of public partners promoted by the Region of Tuscany to promote Tuscany as a key investment destination and attracting, facilitating and retaining investments in the region, and Fondazione Toscana Life Sciences.

The convention provided LDS an opportunity to engage with potential life sciences clients and collaborators, and showcase its products, services and expertise. This year’s theme, “It Starts With One,” highlighted the game-changing impact of small, daily efforts towards scientific breakthroughs. The “It Starts With One” theme perfectly embodies the idea of how even small companies can bring important advances in new drugs or how just one meeting can pave the way to new fruitful synergies.

LDS had a very busy agenda in Philadelphia and is looking forward to transform those first contacts into successful collaborations!

 

https://convention.bio.org/

https://www.investintuscany.com/

Meet In Italy for Life Sciences 2018

LDS has attended the last edition of Meet in Italy for Life Sciences which is the main national matchmaking and update event on topical issues in Life Sciences

From 10-12 October 2018, LDS was present at the fifth edition of Meet in Italy for Life Sciences at Opificio Golinelli, in Bologna, which saw the participation of over 420 organizations from 37 countries.

LDS partecipated at the Brokerage event, where we had the pleasure to meet about 20 partners to discuss new opportunities for collaboration and business. The event is aimed at strengthening the Life Sciences sector and facilitating networking between companies, research centres and laboratories, investors, startups, national and regional institutions, industry trade groups, clusters, technological parks, incubators, universities, etc.

Meet in Italy for Life Sciences 2018 was promoted and organized by the Emilia-Romagna Region with the technical support of ASTER – the Consortium for innovation and technology transfer in Emilia-Romagna and supported by Europen contributes of Emilia-Romagna Region – ERDF ROP 2014-2020.

Bologna 2018

LDS reaffirms commitment to fighting viral diseases: the PANVIR.NET Project

LDS is the leading institution in PANVIR.NET Project together with VisMederi Research srl, Accurange srl, Pharma Development and Services srl, University of Siena, University of Florence, and University of Pisa.

PANVIR.NET is co-financed in the framework of POR FESR Toscana 2014-2020, Azione 1.1.5 sub-azione a1; Bando 2 “Progetti di ricerca e Sviluppo delle PMI”

Objective of PANVIR.NET (Preclinical development of novel panviral agents within a specialized regional network) is to develop new therapies based on broad spectrum antiviral agents against those viruses currently responsible of outbreaks with a potential epidemic or pandemic evolution, thanks to a public-private network localized in Tuscany Region and able to guide and support the antiviral drug discovery and development process.

Recent demographic and climatic changes have caused a wider diffusion of arboviruses such as Dengue, Chikungunya, Zika, West Nile, and novel influenza viruses subtypes, and an increased risk for novel infections or re-activation of persistent infections, such as erpetic infections from cytomegalovirus, Epstein-Barr, herpes simplex type -1 and -2 e varicella-zoster. Broad spectrum antiviral drugs  that target common components present in several viruses could represent a novel strategy to fight viral infections that are currently without any specific drugs, and to limit the selection of resistant viral strains.

Within PANVIR.NET, LDS and its partners aims to identify at least one novel preclinical candidate for the treatment of viral diseases. This will include the definition of all the tests and methods that are necessary to develop new antiviral drugs through the development and consolidation of a specialized regional network.

————————————————-

PANVIR.NET è un Progetto co-finanziato nel quadro del POR FESR Toscana 2014-2020; Azione 1.1.5 sub-azione a1; Bando 2 “Progetti di ricerca e sviluppo delle MPMI”

Obiettivo di PANVIR.NET (Sviluppo preclinico di agenti PANVIRali innovativi all’interno di un NETwork regionale specializzato) è lo sviluppo di nuove terapie basate su agenti antivirali ad ampio spettro contro virus che sono causa di focolai con possibile andamento epidemico o pandemico, all’interno di un network pubblico-privato localizzato in Toscana in grado di supportare e guidare il percorso di sviluppo di farmaci antivirali.

Recenti cambiamenti demografici e climatici hanno portato ad una maggiore diffusione di arbovirus quali Dengue, Chikungunya, Zika, West Nile, e nuovi sottotipi di virus influenzali, e ad un accresciuto rischio di nuove infezioni o di riattivazione di quelle persistenti, tra cui le infezioni erpetiche da citomegalovirus, Epstein-Barr, herpes simplex tipo -1 e -2 e varicella-zoster. Farmaci antivirali ad ampio spettro che bersagliano componenti comuni a più virus, rappresentano una strategia innovativa per contrastare infezioni virali per le quali non esistono farmaci specifici e limitare la selezione di varianti virali resistenti.

In PANVIR.NET, LDS ed i suoi partner intendono identificare almeno un candidato preclinico innovativo per il trattamento di malattie virali oltre a definire i test e le procedure necessarie allo sviluppo di nuovi farmaci antivirali, attaverso lo sviluppo e consolidamento di un network regionale specializzato.

Sostegno finanziario ricevuto dall’Unione: 672 708,97 €